Market Research Report

Product code

974916

Point-of-Care Diagnostics Market for Infectious Diseases by Indication (Chikungunya, COVID-19, Dengue, Ebola, Hepatitis, HIV/AIDS, Influenza, Malaria, Pneumonia, Tuberculosis, and Zika), Type of Technology

Published: September 30, 2020 |

Roots Analysis | 235 Pages | Delivery time: 1-2 business days

Price

Description
Table of Contents
List of Tables

Add to Compare

Title:
Point-of-Care Diagnostics Market for Infectious Diseases
by Indication (Chikungunya, COVID-19, Dengue, Ebola, Hepatitis, HIV/AIDS, Influenza, Malaria, Pneumonia, Tuberculosis, and Zika), Type of Technology (Lateral flow, Molecular diagnostics, Fluorescence immunoassay, Solid phase, and Other technologies) and Geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2020-2030.

Overview:

According to the World Health Organization (WHO), the big three infectious diseases, namely human immunodeficiency virus / acquired immunodeficiency syndrome (HIV / AIDS), malaria and tuberculosis (TB), are reported to be the cause of approximately 2.5 million annual fatalities worldwide. Moreover, the pathogens responsible for causing these diseases are known to undergo selective mutations, which make them resistant to commonly used antibiotics. This impedes the effective treatment of the aforementioned clinical conditions. Since the pathophysiology of such diseases is known to evolve with time, better diagnostic tools with high sensitivity and specificity are required for timely diagnosis and better treatment related decision-making. For diseases of bacterial origin, diagnosis is based on culturing the pathogen; this is considered the current gold standard. Although these methods are highly specific, they are time consuming, requiring three to five days for detecting the responsible pathogen. On the other hand, in case of viral infections, molecular diagnostic platforms, such as next generation sequencing and real-time polymerase chain reactions, are typically used. However, these molecular level analytical techniques are expensive, complicated, and generally inaccessible in resource-limited settings.

Given the aforementioned challenges, the medical industry is consistently engaged in efforts to innovate in assay formats, developing better biosensors, and bioanalytical platforms to expedite the diagnosis process. The concept of point-of-care diagnostics, or rapid diagnostics, has become even more popular with the novel coronavirus outbreak. Unlike the traditional laboratory-based tests, the results of a point-of-care test can be made available instantaneously (as fast as 5 minutes) . This facilitates faster diagnosis and prompt decision making with respect to treatment, thereby, enabling the containment of infectious diseases at an early stage of transmission and preventing outbreaks. Additionally, point-of-care diagnostics have shown to reduce the reliance on presumptive treatment, thereby, helping curb the inappropriate use of antibiotics. Till date, point-of-care diagnostics are widely used for the diagnosis of diseases, such as chikungunya, COVID-19, dengue, hepatitis, malaria, pneumonia, and tuberculosis. In future, we expect such tests / assays to dominate the in vitro diagnostics market.

Scope of the Report:

The 'Point-of-Care Diagnostics Market for Infectious Diseases, 2020-2025' report features an extensive study on point-of-care diagnostics that are either commercialized or are under development for diagnosis of different types of infections. In addition, it features an elaborate discussion on the likely future opportunity associated with such tools, over the next five years. Amongst other elements, the report includes:

A detailed review of the overall landscape of point-of-care diagnostics for COVID-19, providing information on current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and device / platform), type of technology (fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, vertical flow, and others), type of sample (blood, nasal / nasopharyngeal secretions, sputum, urine, and others), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the report presents the details of the companies developing these point-of-care diagnostics, including information on year of establishment, company size and location of headquarters.

A detailed review of the overall landscape of Point-of-Care Diagnostics for tropical diseases, providing information on current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and device / platform), type of technology (flow-through, fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, and others), target disease indication (chikungunya, dengue, Ebola, malaria, and zika), type of sample (blood, sputum, and urine), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the report presents the details of the companies developing these point-of-care diagnostics, including information on year of establishment, company size and location of headquarters.

A detailed review of the overall landscape of point-of-care diagnostics for respiratory infections, providing information on current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and device / platform), type of technology (fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, and others), target disease indication (influenza, pneumonia, and tuberculosis), type of sample (blood, cerebrospinal fluid, nasal / nasopharyngeal secretions, sputum, urine, and others), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the report presents the details of the companies developing these point-of-care diagnostics, including information on year of establishment, company size and location of headquarters.

A detailed review of the overall landscape of point-of-care diagnostics for HIV/AIDS and hepatitis, providing information on current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and device / platform), type of technology (flow-through, fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, vertical flow, and others), target disease indication (hepatitis A, hepatitis B, hepatitis C, and HIV/AIDS), type of sample (blood, feces, oral fluid, and urine), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the report presents the details of the companies developing these point-of-care diagnostics, including information on year of establishment, company size and location of headquarters.

A detailed study of the overall landscape of point-of-care diagnostics for infectious diseases, featuring analyses based on a number of relevant parameters, such as type of technology (flow-through, fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, vertical flow, and others), target disease indication (chikungunya, COVID-19, dengue, Ebola, hepatitis, HIV/AIDS, influenza, malaria, pneumonia, tuberculosis, and zika), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes).

An analysis of the partnerships that have been inked by stakeholders in this domain, during the period between January 2018 and July 2020, covering distribution and supply agreements, product development and commercialization agreements, commercialization agreements, mergers and acquisitions, product development and manufacturing agreements, research and development agreements, and product / technology integration agreements.

A detailed analysis on acquisition targets, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2018, and offering a means for other industry stakeholders to identify potential acquisition targets.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities. Based on various parameters, such as number of available / under development products, average price of point-of-care tests and estimated annual adoption rates, we have provided an informed estimate on the likely evolution of the market over the period 2020-2025. The report also features the likely distribution of the current and forecasted opportunity across [A] target disease indications (chikungunya, COVID-19, dengue, Ebola, hepatitis, HIV/AIDS, influenza, malaria, pneumonia, tuberculosis, and zika), [B] type of technology (lateral flow, molecular diagnostics, fluorescence immunoassay, solid phase, and others), and [C] key geographical regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

Reuven Duer, Founder and CEO, Proactive Diagnostics

Giffin Daughtridge, CEO, UrSure

Abhinav Thakur, Managing Director, Accurex Biomedical

Gerrit Van Roekel, Director of Business Development, Hemex Health

Sofiane Bennacer, Business Development Manager, Credo Diagnostics Biomedical

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

What are the prevalent trends within the point-of-care diagnostics market?

What are the key technologies being used in point-of-care diagnostics?

Who are the leading developers of point-of-care diagnostics for COVID-19?

Who are the leading developers of point-of-care diagnostics for tropical diseases (chikungunya, dengue, Ebola, malaria, and zika) and respiratory infections (influenza, pneumonia, and tuberculosis)?

Who are the leading developers of point-of-care diagnostics for HIV/AIDS and hepatitis?

Which partnership models are commonly adopted by stakeholders in this industry?

How is the current and future market opportunity likely to be distributed across key market segments and geographical regions?

Chapter Outlines:

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of the market for point-of-care diagnostics for infectious diseases and its likely evolution in the short-mid-term and long term.

Chapter 3 provides an introduction to point-of-care diagnostics. In addition, the chapter discusses the growing incidence of infectious diseases worldwide, elaborating on the importance of point-of-care diagnostics for early and accurate diagnosis. It also highlights the characteristics of an ideal point-of-care diagnostic and the various technology platforms that are currently being used for development of such tests. It also features a brief discussion on the opportunities and the likely future trends in this field.

Chapter 4 provides information on nearly 180 point-of-care diagnostics that are either available or being developed for the diagnosis of COVID-19, and a detailed analysis based on a number of relevant parameters, such as current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and device / platform), type of technology (fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, vertical flow, and others), type of sample (blood, nasal / nasopharyngeal secretions, sputum, urine, and others), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the chapter includes an analysis of the companies engaged in developing point-of-care diagnostics for COVID-19, based on year of establishment, company size and location of headquarters.

Chapter 5 provides information on nearly 515 point-of-care diagnostics that are either available or being developed for the diagnosis of tropical diseases, and a detailed analysis based on a number of relevant parameters, such as current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and device / platform), type of technology (flow-through, fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, and others), target disease indications (chikungunya, dengue, Ebola, malaria, and zika), type of sample (blood, sputum, and urine), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the chapter includes an analysis of the companies engaged in developing point-of-care diagnostics for tropical diseases, based on year of establishment, company size and location of headquarters.

Chapter 6 provides information on nearly 280 point-of-care diagnostics that are either available or being developed for the diagnosis of respiratory infections, and a detailed analysis based on a number of relevant parameters, such as current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and device / platform), type of technology (fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, and others), target disease indications (influenza, pneumonia, and tuberculosis), type of sample (blood, cerebrospinal fluid, nasal / nasopharyngeal secretions, sputum, urine, and others), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the chapter includes an analysis of the companies engaged in developing point-of-care diagnostics for respiratory infections, based on year of establishment, company size and location of headquarters.

Chapter 7 provides information on nearly 610 point-of-care diagnostics that are either available or being developed for the diagnosis of HIV/AIDS and hepatitis, and a detailed analysis based on a number of relevant parameters, such as current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and device / platform), type of technology (flow-through, fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, vertical flow, and others), target disease indications (hepatitis A, hepatitis B, hepatitis C, and HIV/AIDS), type of sample (blood, feces, oral fluid, and urine), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the chapter includes an analysis of the companies engaged in developing point-of-care diagnostics for HIV/AIDS and hepatitis, based on year of establishment, company size and location of headquarters.

Chapter 8 presents a study of the current market landscape of point-of-care diagnostics for infectious diseases, featuring detailed analyses based on parameters, such as type of technology (flow-through, fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, vertical flow, and others), target disease indications (chikungunya, COVID-19, dengue, Ebola, hepatitis, HIV/AIDS, influenza, malaria, pneumonia, tuberculosis, and zika), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes).

Chapter 9 features an analysis of the various partnerships and collaborations that have been inked by stakeholders in this domain, during 2018-2020. It includes a brief description of partnership models (such as distribution and supply agreements, product development and commercialization agreements, commercialization agreements, mergers and acquisitions, product development and manufacturing agreements, research and development agreements, and product / technology integration agreements) adopted by the stakeholders. In addition, it includes analyses based on year of partnership, type of partnership, type of product, target disease indication, and geographical location of companies involved.

Chapter 10 provides a detailed acquisition target analysis, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2018, and offering a means for other industry stakeholders to identify potential acquisition targets.

Chapter 11 features an insightful market forecast analysis, highlighting the likely growth of point-of-care diagnostics for infectious diseases market, till the year 2025. In order to provide details on the future opportunity, our projections have been segmented on the basis [A] target disease indications (chikungunya, COVID-19, dengue, Ebola, hepatitis, HIV/AIDS, influenza, malaria, pneumonia, tuberculosis, and zika), [B] type of technology (lateral flow assay, molecular diagnostics, fluorescence immunoassay, solid phase assay, and others), and [C] key geographical regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Chapter 12 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented a brief overview of the companies and details of our conversations held with Reuven Duer (Founder and CEO, Proactive Diagnostics), Giffin Daughtridge (CEO, UrSure), Abhinav Thakur (Managing Director, Accurex Biomedical), Gerrit Van Roekel (Director of Business Development, Hemex Health), and Sofiane Bennacer (Business Development Manager, Credo Diagnostics Biomedical).

Chapter 13 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the point-of-care diagnostics industry.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Overview of Point-of-Care Diagnostics (POCDs)
- 3.2.1. Characteristics of an Ideal Point-of-Care Diagnostic
- 3.2.2. Technologies Used in Point-of-Care Diagnostics of Infectious Diseases
3.3. Challenges Associated with Point-of-Care Diagnostics
3.4. Future Perspectives

4. CURRENT MARKET LANDSCAPE (FOCUS ON COVID-19)

4.1. Chapter Overview
4.2. Point-of-Care Diagnostics for COVID-19: List of Products
- 4.2.1. Analysis by Status of Development
- 4.2.2. Analysis by Type of Product
- 4.2.3. Analysis by Type of Technology
- 4.2.4. Analysis by Type of Sample
- 4.2.5. Analysis by Sensitivity Range
- 4.2.6. Analysis by Specificity Range
- 4.2.7. Analysis by Turnaround Time
4.3. Point-of-Care Diagnostics for COVID-19: List of Developers
- 4.3.1. Analysis by Year of Establishment
- 4.3.2. Analysis by Company Size and Geographical Location
- 4.3.3. Leading Developers: Analysis by Number of Products
- 4.3.4. World Map Representation: Analysis by Regional Activity

5. CURRENT MARKET LANDSCAPE (FOCUS ON TROPICAL DISEASES)

5.1. Chapter Overview
5.2. Point-of-Care Diagnostics for Tropical Diseases: List of Products
- 5.2.1. Analysis by Status of Development
- 5.2.2. Analysis by Type of Product
- 5.2.3. Analysis by Type of Technology
- 5.2.4. Analysis by Target Disease Indication
- 5.2.5. Analysis by Type of Sample
- 5.2.6. Analysis by Sensitivity Range
- 5.2.7. Analysis by Specificity Range
- 5.2.8. Analysis by Turnaround Time
5.3. Point-of-Care Diagnostics for Tropical Diseases: List of Developers
- 5.3.1. Analysis by Year of Establishment
- 5.3.2. Analysis by Company Size and Geographical Location
- 5.3.3. Leading Developers: Analysis by Number of Products
- 5.3.4. World Map Representation: Analysis by Regional Activity

6. CURRENT MARKET LANDSCAPE (FOCUS ON RESPIRATORY INFECTIONS)

6.1. Chapter Overview
6.2. Point-of-Care Diagnostics for Respiratory Infections: List of Products
- 6.2.1. Analysis by Status of Development
- 6.2.2. Analysis by Type of Product
- 6.2.3. Analysis by Type of Technology
- 6.2.4. Analysis by Target Disease Indication
- 6.2.5. Analysis by Type of Sample
- 6.2.6. Analysis by Sensitivity Range
- 6.2.7. Analysis by Specificity Range
- 6.2.8. Analysis by Turnaround Time
6.3. Point-of-Care Diagnostics for Respiratory Infections: List of Developers
- 6.3.1. Analysis by Year of Establishment
- 6.3.2. Analysis by Company Size and Geographical Location
- 6.3.3. Leading Developers: Analysis by Number of Products
- 6.3.4. World Map Representation: Analysis by Regional Activity

7. CURRENT MARKET LANDSCAPE (FOCUS ON HIV/AIDS AND HEPATITIS)

7.1. Chapter Overview
7.2. Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: List of Products
- 7.2.1. Analysis by Status of Development
- 7.2.2. Analysis by Type of Product
- 7.2.3. Analysis by Type of Technology
- 7.2.4. Analysis by Target Disease Indication
- 7.2.5. Analysis by Type of Sample
- 7.2.6. Analysis by Sensitivity Range
- 7.2.7. Analysis by Specificity Range
- 7.2.8. Analysis by Turnaround Time
7.3. Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: List of Developers
- 7.3.1. Analysis by Year of Establishment
- 7.3.2. Analysis by Company Size and Geographical Location
- 7.3.3. Leading Developers: Analysis by Number of Products
- 7.3.4. World Map Representation: Analysis by Regional Activity

8. OVERALL MARKET LANDSCAPE

8.1. Chapter Overview
8.2. Analysis by Type of Technology
8.3. Analysis by Target Disease Indication
8.4. Analysis by Sensitivity Range
8.5. Analysis by Specificity Range
8.6. Analysis by Turnaround Time

9. PARTNERSHIPS AND COLLABORATIONS

9.1. Chapter Overview
9.2. Partnership Models
9.3. Point-of-Care Diagnostics for Infectious Diseases: List of Partnerships and Collaborations
- 9.3.1. Analysis by Year of Partnership
- 9.3.2. Analysis by Type of Partnership
- 9.3.3. Analysis by Type of Product
- 9.3.4. Analysis by Target Disease Indication
- 9.3.5. Analysis by Year and Type of Partner
- 9.3.6. Most Active Players: Analysis by Number of Partnerships
- 9.3.7. Regional Analysis
- 9.3.8. Intercontinental and Intracontinental Agreements

10. KEY ACQUISITION TARGETS

10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Scoring Criteria and Key Assumptions
10.4. Potential Strategic Acquisition Targets in North America
10.5. Potential Strategic Acquisition Targets in Europe
10.6. Potential Strategic Acquisition Targets in Asia-Pacific
10.7. Potential Strategic Acquisition Targets in Latin America
10.8. Potential Strategic Acquisition Targets in Middle East, North Africa, and Rest of the World
10.9. Concluding Remarks

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS

11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020-2025
11.4. Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Target Disease Indication
- 11.4.1. Point-of-Care Diagnostics Market for COVID-19, 2020-2025
- 11.4.2. Point-of-Care Diagnostics Market for Chikungunya, 2020-2025
- 11.4.3. Point-of-Care Diagnostics Market for Dengue, 2020-2025
- 11.4.4. Point-of-Care Diagnostics Market for Ebola, 2020-2025
- 11.4.5. Point-of-Care Diagnostics Market for Hepatitis, 2020-2025
- 11.4.6. Point-of-Care Diagnostics Market for HIV/AIDS, 2020-2025
- 11.4.7. Point-of-Care Diagnostics Market for Influenza, 2020-2025
- 11.4.8. Point-of-Care Diagnostics Market for Malaria, 2020-2025
- 11.4.9. Point-of-Care Diagnostics Market for Pneumonia, 2020-2025
- 11.4.10. Point-of-Care Diagnostics Market for Tuberculosis, 2020-2025
- 11.4.11. Point-of-Care Diagnostics Market for Zika, 2020-2025
11.5. Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Type of Technology
- 11.5.1. Point-of-Care Diagnostics for Infectious Diseases Market for Lateral Flow Assay, 2020-2025
- 11.5.2. Point-of-Care Diagnostics for Infectious Diseases Market for Molecular Diagnostics, 2020-2025
- 11.5.3. Point-of-Care Diagnostics for Infectious Diseases Market for Fluorescence Immunoassay, 2020-2025
- 11.5.4. Point-of-Care Diagnostics for Infectious Diseases Market for Solid Phase Assay, 2020-2025
- 11.5.5. Point-of-Care Diagnostics for Infectious Diseases Market for Other Technologies, 2020-2025
11.6. Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Geography
- 11.6.1. Point-of-Care Diagnostics for Infectious Diseases Market in the US, 2020-2025
- 11.6.2. Point-of-Care Diagnostics for Infectious Diseases Market in Canada, 2020-2025
- 11.6.3. Point-of-Care Diagnostics for Infectious Diseases Market in the UK, 2020-2025
- 11.6.4. Point-of-Care Diagnostics for Infectious Diseases Market in Germany, 2020-2025
- 11.6.5. Point-of-Care Diagnostics for Infectious Diseases Market in Spain, 2020-2025
- 11.6.6. Point-of-Care Diagnostics for Infectious Diseases Market in France, 2020-2025
- 11.6.7. Point-of-Care Diagnostics for Infectious Diseases Market in Italy, 2020-2025
- 11.6.8. Point-of-Care Diagnostics for Infectious Diseases Market in China, 2020-2025
- 11.6.9. Point-of-Care Diagnostics for Infectious Diseases Market in India, 2020-2025
- 11.6.10. Point-of-Care Diagnostics for Infectious Diseases Market in Japan, 2020-2025
- 11.6.11. Point-of-Care Diagnostics for Infectious Diseases Market in Australia, 2020-2025
- 11.6.12. Point-of-Care Diagnostics for Infectious Diseases Market in Brazil, 2020-2025
- 11.6.13. Point-of-Care Diagnostics for Infectious Diseases Market in Argentina, 2020-2025
- 11.6.14. Point-of-Care Diagnostics for Infectious Diseases Market in Saudi Arabia, 2020-2025
- 11.6.15. Point-of-Care Diagnostics for Infectious Diseases Market in UAE, 2020-2025
- 11.6.16. Point-of-Care Diagnostics for Infectious Diseases Market in Egypt, 2020-2025
- 11.6.17. Point-of-Care Diagnostics for Infectious Diseases Market in South Africa, 2020-2025

12. EXECUTIVE INSIGHTS

12.1. Chapter Overview
12.2. Proactive Diagnostics
- 12.2.1. Company Snapshot
- 12.2.2. Interview Transcript: Reuven Duer, Founder and Chief Executive Officer
12.3. UrSure
- 12.3.1. Company Snapshot
- 12.3.2. Interview Transcript: Giffin Daughtridge, Chief Executive Officer
12.4. Accurex Biomedical
- 12.4.1. Company Snapshot
- 12.4.2. Interview Transcript: Abhinav Thakur, Managing Director
12.5. Hemex Health
- 12.5.1. Company Snapshot
- 12.5.2. Interview Transcript: Gerrit Van Roekel, Director of Business Development
12.6. Credo Diagnostics Biomedical
- 12.6.1. Company Snapshot
- 12.6.2. Interview Transcript: Sofiane Bennacer, Business Development Manager

13. CONCLUDING REMARKS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 The ASSURED Criteria for an Ideal Point-of-Care Diagnostics
Figure 3.2 Technologies Used in Point-of-Care Diagnostics for Infectious Diseases
Figure 4.1 Point-of-Care Diagnostics for COVID-19: Distribution by Status of Development
Figure 4.2 Point-of-Care Diagnostics for COVID-19: Distribution by Type of Product
Figure 4.3 Point-of-Care Diagnostics for COVID-19: Distribution by Type of Technology
Figure 4.4 Point-of-Care Diagnostics for COVID-19: Distribution by Type of Sample
Figure 4.5 Point-of-Care Diagnostics for COVID-19: Distribution by Sensitivity Range
Figure 4.6 Point-of-Care Diagnostics for COVID-19: Distribution by Specificity Range
Figure 4.7 Point-of-Care Diagnostics for COVID-19: Distribution by Turnaround Time
Figure 4.8 Point-of-Care Diagnostics for COVID-19: Distribution of Developers by Year of Establishment
Figure 4.9 Point-of-Care Diagnostics for COVID-19: Distribution of Developers by Company Size and Geographical Location
Figure 4.10 Leading Players: Distribution by Number of Products
Figure 4.11 World Map Representation: Distribution by Regional Activity
Figure 5.1 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Status of Development
Figure 5.2 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Type of Product
Figure 5.3 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Type of Technology
Figure 5.4 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Target Disease Indication
Figure 5.5 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Type of Sample
Figure 5.6 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Sensitivity Range
Figure 5.7 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Specificity Range
Figure 5.8 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Turnaround Time
Figure 5.9 Point-of-Care Diagnostics for Tropical Diseases: Distribution of Developers by Year of Establishment
Figure 5.10 Point-of-Care Diagnostics for Tropical Diseases: Distribution of Developers by Company Size and Geographical Location
Figure 5.11 Leading Players: Distribution by Number of Products
Figure 5.12 World Map Representation: Distribution by Regional Activity
Figure 6.1 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Status of Development
Figure 6.2 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Type of Product
Figure 6.3 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Type of Technology
Figure 6.4 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Target Disease Indication
Figure 6.5 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Type of Sample
Figure 6.6 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Sensitivity Range
Figure 6.7 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Specificity Range
Figure 6.8 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Turnaround Time
Figure 6.9 Point-of-Care Diagnostics for Respiratory Infections: Distribution of Developers by Year of Establishment
Figure 6.10 Point-of-Care Diagnostics for Respiratory Infections: Distribution of Developers by Company Size and Geographical Location
Figure 6.11 Leading Players: Distribution by Number of Products
Figure 6.12 World Map Representation: Distribution by Regional Activity
Figure 7.1 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Status of Development
Figure 7.2 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Type of Product
Figure 7.3 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Type of Technology
Figure 7.4 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Target Disease Indication
Figure 7.5 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Type of Sample
Figure 7.6 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Sensitivity Range
Figure 7.7 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Specificity Range
Figure 7.8 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Turnaround Time
Figure 7.9 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution of Developers by Year of Establishment
Figure 7.10 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution of Developers by Company Size and Geographical Location
Figure 7.11 Leading Players: Distribution by Number of Products
Figure 7.12 World Map Representation: Distribution by Regional Activity
Figure 8.1 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Type of Technology
Figure 8.2 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Target Disease Indication
Figure 8.3 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Sensitivity Range
Figure 8.4 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Specificity Range
Figure 8.5 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Turnaround Time
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2020 (till July)
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Product
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Figure 9.6 Partnerships and Collaborations: Distribution by Target Disease Indication
Figure 9.7 Partnerships and Collaborations: Distribution by Year and Type of Partner
Figure 9.8 Most Active Players: Distribution by Number of Partnerships
Figure 9.9 Partnerships and Collaborations: Regional Distribution
Figure 9.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Likely Acquisition Targets: Geographical Distribution
Figure 11.1 Global Point-of-Care for Infectious Diseases Market, 2020-2025 (USD Million)
Figure 11.2 Global Point-of-Care for Infectious Diseases Market, 2020 and 2025: Distribution by Target Disease Indication (USD Million)
Figure 11.3 Point-of-Care Diagnostics Market for COVID-19, 2020-2025 (USD Million)
Figure 11.4 Point-of-Care Diagnostics Market for Chikungunya, 2020-2025 (USD Million)
Figure 11.5 Point-of-Care Diagnostics Market for Dengue, 2020-2025 (USD Million)
Figure 11.6 Point-of-Care Diagnostics Market for Ebola, 2020-2025 (USD Million)
Figure 11.7 Point-of-Care Diagnostics Market for Hepatitis, 2020-2025 (USD Million)
Figure 11.8 Point-of-Care Diagnostics Market for HIV/AIDS, 2020-2025 (USD Million)
Figure 11.9 Point-of-Care Diagnostics Market for Influenza, 2020-2025 (USD Million)
Figure 11.10 Point-of-Care Diagnostics Market for Malaria, 2020-2025 (USD Million)
Figure 11.11 Point-of-Care Diagnostics Market for Pneumonia, 2020-2025 (USD Million)
Figure 11.12 Point-of-Care Diagnostics Market for Tuberculosis, 2020-2025 (USD Million)
Figure 11.13 Point-of-Care Diagnostics Market for Zika, 2020-2025 (USD Million)
Figure 11.14 Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Type of Technology (USD Million)
Figure 11.15 Point-of-Care Diagnostics for Infectious Diseases Market for Lateral Flow Assay, 2020-2025 (USD Million)
Figure 11.16 Point-of-Care Diagnostics for Infectious Diseases Market for Molecular Diagnostics, 2020-2025 (USD Million)
Figure 11.17 Point-of-Care Diagnostics for Infectious Diseases Market for Fluorescence Immunoassay, 2020-2025 (USD Million)
Figure 11.18 Point-of-Care Diagnostics for Infectious Diseases Market for Solid Phase Assay, 2020-2025 (USD Million)
Figure 11.19 Point-of-Care Diagnostics for Infectious Diseases Market for Other Technologies, 2020-2025 (USD Million)
Figure 11.20 Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Geography (USD Million)
Figure 11.21 Point-of-Care Diagnostics for Infectious Diseases Market in the US, 2020-2025 (USD Million)
Figure 11.22 Point-of-Care Diagnostics for Infectious Diseases Market in Canada, 2020-2025 (USD Million)
Figure 11.23 Point-of-Care Diagnostics for Infectious Diseases Market in the UK, 2020-2025 (USD Million)
Figure 11.24 Point-of-Care Diagnostics for Infectious Diseases Market in Germany, 2020-2025 (USD Million)
Figure 11.25 Point-of-Care Diagnostics for Infectious Diseases Market in Spain, 2020-2025 (USD Million)
Figure 11.26 Point-of-Care Diagnostics for Infectious Diseases Market in France, 2020-2025 (USD Million)
Figure 11.27 Point-of-Care Diagnostics for Infectious Diseases Market in Italy, 2020-2025 (USD Million)
Figure 11.28 Point-of-Care Diagnostics for Infectious Diseases Market in China, 2020-2025 (USD Million)
Figure 11.29 Point-of-Care Diagnostics for Infectious Diseases Market in India, 2020-2025 (USD Million)
Figure 11.30 Point-of-Care Diagnostics for Infectious Diseases Market in Japan, 2020-2025 (USD Million)
Figure 11.31 Point-of-Care Diagnostics for Infectious Diseases Market in Australia, 2020-2025 (USD Million)
Figure 11.32 Point-of-Care Diagnostics for Infectious Diseases Market in Brazil, 2020-2025 (USD Million)
Figure 11.33 Point-of-Care Diagnostics for Infectious Diseases Market in Argentina, 2020-2025 (USD Million)
Figure 11.34 Point-of-Care Diagnostics for Infectious Diseases in Saudi Arabia, 2020-2025 (USD Million)
Figure 11.35 Point-of-Care Diagnostics for Infectious Diseases Market in UAE, 2020-2025 (USD Million)
Figure 11.36 Point-of-Care Diagnostics for Infectious Diseases Market in Egypt, 2020-2025 (USD Million)
Figure 11.37 Point-of-Care Diagnostics for Infectious Diseases Market in South Africa, 2020-2025 (USD Million)

List Of Tables

Table 4.1 Point-of-Care Diagnostics for COVID-19: List of Products
Table 4.2 Point-of-Care Diagnostics for COVID-19: List of Developers
Table 5.1 Point-of-Care Diagnostics for Tropical Diseases: List of Products
Table 5.2 Point-of-Care Diagnostics for Tropical Diseases: List of Developers
Table 6.1 Point-of-Care Diagnostics for Respiratory Infections: List of Products
Table 6.2 Point-of-Care Diagnostics for Respiratory Infections: List of Developers
Table 7.1 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: List of Products
Table 7.2 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: List of Developers
Table 9.1 Point-of-Care Diagnostics for Infectious Diseases: List of Partnerships and Collaborations
Table 10.1 North America: Likely Targets for Acquisition
Table 10.2 Europe: Likely Targets for Acquisition
Table 10.3 Asia-Pacific: Likely Targets for Acquisition
Table 10.4 Latin America: Likely Targets for Acquisition
Table 10.5 Middle East, North Africa, and Rest of the World: Likely Targets for Acquisition
Table 12.1 Proactive Diagnostics: Company Snapshot
Table 12.2 UrSure: Company Snapshot
Table 12.3 Accurex Biomedical: Company Snapshot
Table 12.4 Hemex Health: Company Snapshot
Table 12.5 Credo Diagnostics Biomedical: Company Snapshot
Table 14.1 Point-of-Care Diagnostics for COVID-19: Distribution by Status of Development
Table 14.2 Point-of-Care Diagnostics for COVID-19: Distribution by Type of Product
Table 14.3 Point-of-Care Diagnostics for COVID-19: Distribution by Type of Technology
Table 14.4 Point-of-Care Diagnostics for COVID-19: Distribution by Type of Sample
Table 14.5 Point-of-Care Diagnostics for COVID-19: Distribution by Sensitivity Range
Table 14.6 Point-of-Care Diagnostics for COVID-19: Distribution by Specificity Range
Table 14.7 Point-of-Care Diagnostics for COVID-19: Distribution by Turnaround Time
Table 14.8 Point-of-Care Diagnostics for COVID-19: Distribution of Developers by Year of Establishment
Table 14.9 Point-of-Care Diagnostics for COVID-19: Distribution of Developers by Company Size and Geographical Location
Table 14.10 Leading Players: Distribution by Number of Products
Table 14.11 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Status of Development
Table 14.12 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Type of Product
Table 14.13 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Type of Technology
Table 14.14 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Target Disease Indication
Table 14.15 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Type of Sample
Table 14.16 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Sensitivity Range
Table 14.17 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Specificity Range
Table 14.18 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Turnaround Time
Table 14.19 Point-of-Care Diagnostics for Tropical Diseases: Distribution of Developers by Year of Establishment
Table 14.20 Point-of-Care Diagnostics for Tropical Diseases: Distribution of Developers by Company Size and Geographical Location
Table 14.21 Leading Players: Distribution by Number of Products
Table 14.22 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Status of Development
Table 14.23 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Type of Product
Table 14.24 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Type of Technology
Table 14.25 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Target Disease Indication
Table 14.26 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Type of Sample
Table 14.27 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Sensitivity Range
Table 14.28 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Specificity Range
Table 14.29 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Turnaround Time
Table 14.30 Point-of-Care Diagnostics for Respiratory Infections: Distribution of Developers by Year of Establishment
Table 14.31 Point-of-Care Diagnostics for Respiratory Infections: Distribution of Developers by Company Size and Geographical Location
Table 14.32 Leading Players: Distribution by Number of Products
Table 14.33 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Status of Development
Table 14.34 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Type of Product
Table 14.35 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Type of Technology
Table 14.36 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Target Disease Indication
Table 14.37 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Type of Sample
Table 14.38 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Sensitivity Range
Table 14.39 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Specificity Range
Table 14.40 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Turnaround Time
Table 14.41 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution of Developers by Year of Establishment
Table 14.42 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution of Developers by Company Size and Geographical Location
Table 14.43 Leading Players: Distribution by Number of Products
Table 14.44 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Type of Technology
Table 14.45 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Target Disease Indication
Table 14.46 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Sensitivity Range
Table 14.47 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Specificity Range
Table 14.48 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Turnaround Time
Table 14.49 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2020 (till July)
Table 14.50 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.51 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 14.52 Partnerships and Collaborations: Distribution by Type of Product
Table 14.53 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Table 14.54 Partnerships and Collaborations: Distribution by Target Disease Indication
Table 14.55 Partnerships and Collaborations: Distribution by Year and Type of Partner
Table 15.56 Most Active Players: Distribution by Number of Partnerships
Table 14.57 Partnerships and Collaborations: Regional Distribution
Table 14.58 Likely Acquisition Targets: Geographical Distribution
Table 14.59 Global Point-of-Care for Infectious Diseases Market, 2020-2025 (USD Million)
Table 14.60 Global Point-of-Care for Infectious Diseases Market, 2020 and 2025: Distribution by Target Disease Indication (USD Million)
Table 14.61 Point-of-Care Diagnostics Market for COVID-19, 2020-2025 (USD Million)
Table 14.62 Point-of-Care Diagnostics Market for Chikungunya, 2020-2025 (USD Million)
Table 14.63 Point-of-Care Diagnostics Market for Dengue, 2020-2025 (USD Million)
Table 14.64 Point-of-Care Diagnostics Market for Ebola, 2020-2025 (USD Million)
Table 14.65 Point-of-Care Diagnostics Market for Hepatitis, 2020-2025 (USD Million)
Table 14.66 Point-of-Care Diagnostics Market for HIV/AIDS, 2020-2025 (USD Million)
Table 14.67 Point-of-Care Diagnostics Market for Influenza, 2020-2025 (USD Million)
Table 14.68 Point-of-Care Diagnostics Market for Malaria, 2020-2025 (USD Million)
Table 14.69 Point-of-Care Diagnostics Market for Pneumonia, 2020-2025 (USD Million)
Table 14.70 Point-of-Care Diagnostics Market for Tuberculosis, 2020-2025 (USD Million)
Table 14.71 Point-of-Care Diagnostics Market for Zika, 2020-2025 (USD Million)
Table 14.72 Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Type of Technology (USD Million)
Table 14.73 Point-of-Care Diagnostics for Infectious Diseases Market for Lateral Flow Assay, 2020-2025 (USD Million)
Table 14.74 Point-of-Care Diagnostics for Infectious Diseases Market for Molecular Diagnostics, 2020-2025 (USD Million)
Table 14.75 Point-of-Care Diagnostics for Infectious Diseases Market for Fluorescence Immunoassay, 2020-2025 (USD Million)
Table 14.76 Point-of-Care Diagnostics for Infectious Diseases Market for Solid Phase Assay, 2020-2025 (USD Million)
Table 14.77 Point-of-Care Diagnostics for Infectious Diseases Market for Other Technologies, 2020-2025 (USD Million)
Table 14.78 Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Geography (USD Million)
Table 14.79 Point-of-Care Diagnostics for Infectious Diseases Market in the US, 2020-2025 (USD Million)
Table 14.80 Point-of-Care Diagnostics for Infectious Diseases Market in Canada, 2020-2025 (USD Million)
Table 14.81 Point-of-Care Diagnostics for Infectious Diseases in the UK, 2020-2025 (USD Million)
Table 14.82 Point-of-Care Diagnostics for Infectious Diseases Market in Germany, 2020-2025 (USD Million)
Table 14.83 Point-of-Care Diagnostics for Infectious Diseases Market in Spain, 2020-2025 (USD Million)
Table 14.84 Point-of-Care Diagnostics for Infectious Diseases Market in France, 2020-2025 (USD Million)
Table 14.85 Point-of-Care Diagnostics for Infectious Diseases Market in Italy, 2020-2025 (USD Million)
Table 14.86 Point-of-Care Diagnostics for Infectious Diseases Market in China, 2020-2025 (USD Million)
Table 14.87 Point-of-Care Diagnostics for Infectious Diseases Market in India, 2020-2025 (USD Million)
Table 14.88 Point-of-Care Diagnostics for Infectious Diseases Market in Japan, 2020-2025 (USD Million)
Table 14.89 Point-of-Care Diagnostics for Infectious Diseases Market in Australia, 2020-2025 (USD Million)
Table 14.90 Point-of-Care Diagnostics for Infectious Diseases Market in Brazil, 2020-2025 (USD Million)
Table 14.91 Point-of-Care Diagnostics for Infectious Diseases Market in Argentina, 2020-2025 (USD Million)
Table 14.92 Point-of-Care Diagnostics for Infectious Diseases Market in Saudi Arabia, 2020-2025 (USD Million)
Table 14.93 Point-of-Care Diagnostics for Infectious Diseases Market in UAE, 2020-2025 (USD Million)
Table 14.94 Point-of-Care Diagnostics for Infectious Diseases Market in Egypt, 2020-2025 (USD Million)
Table 14.95 Point-of-Care Diagnostics for Infectious Diseases Market in South Africa, 2020-2025 (USD Million)

Listed Company 1. 3M Health Care 2. A. Menarini Diagnostics 3. AAZ-LMB 4. Abacus Diagnostica 5. Abingdon Health 6. Abionic 7. Accel Diagnostics 8. Access Bio 9. AccuBioTech 10. Accurex Biomedical 11. Achira Labs 12. ACON Laboratories 13. Acro Biotech 14. Actionmed Medical Equipment Trading 15. ADS Biotec 16. ADVAITE 17. Advy Chemical 18. AgPlus Diagnostics 19. Aidian 20. AIL Dixon Technologies 21. AKO MED 22. Akonni Biosystems 23. ALAB 24. Alere 25. AlphaSIP Laboratories 26. ALUXBIO 27. American Bio Medica 28. American Leprosy Missions 29. American Screening 30. AMS UK 31. Anamol Laboratories 32. Anhui DeepBlue Medical Technology 33. Antagen Pharmaceuticals 34. Anteo Diagnostics 35. ApolloDx 36. Aquila Diagnostic Systems 37. Arbor Vita 38. ArcDia International 39. ARKRAY 40. ARKRAY Healthcare 41. Artron Laboratories 42. Asan Pharmaceutical 43. Ativa Medical 44. Atlas Link 45. Atlas Medical 46. Atomo Diagnostics 47. Augurix 48. Autobio Diagnostics 49. Avacta 50. Aviana Molecular Technologies 51. Axxin 52. Aytu BioScience 53. BBI Solutions 54. Becton, Dickinson 55. Bedford Biotech Nigeria 56. Beijing Hotgen Biotech 57. Beijing Kewei Clinical Diagnostic Reagent 58. Beijing Wantai Biological Pharmacy 59. BGI Group 60. Bhat Bio-tech India 61. BHR Pharmaceuticals 62. Biko 63. binx health 64. BioFab 65. BioFire Diagnostics 66. Biofootprints Healthcare 67. Biogate Laboratories 68. BIOgenetiX 69. Biolidics 70. bioLytical Laboratories 71. Bio-Manguinhos 72. Biomedical Advanced Research and Development Authority (BARDA) 73. BioMedomics 74. Biomeme 75. bioMérieux 76. Bionor 77. Biopanda Reagents 78. BioPorto Diagnostics 79. Bio-Rad Laboratories 80. Biosensia 81. Biosensorix 82. BioSpeedia 83. BioSure (UK) 84. biosurfit 85. Biosynex 86. Biotec Laboratories 87. Biozek medical 88. BluSense Diagnostics 89. Boditech Med 90. Bosch Healthcare Solutions 91. Brevitest Technologies 92. Bright Machines 93. Broad Institute 94. BTNX 95. Bundi International Diagnostics 96. Calypte Biomedical 97. Calyx Biotech 98. Canon Medical Systems 99. Carpegen 100. Cascade Biosystems 101. Cavidi 102. Cellex 103. Cellmic 104. Cepheid 105. CerTest Biotec 106. Chaim Sheba Medical Center 107. Checkable Medical 108. Chembio Diagnostic Systems 109. Chester County Health Department 110. CIGA Healthcare 111. CK Life Sciences 112. Clinton Health Access Initiative 113. Concepta 114. Confirm BioSciences 115. Corgenix Medical 116. Coris BioConcept 117. Creative Diagnostics 118. Credo Diagnostics Biomedical 119. CTK Biotech 120. Cue Health 121. Curetis 122. Curiosity Diagnostics 123. Cyient 124. Cypress Diagnostics 125. Cytiva 126. Datametrex AI 127. DCL Laboratory Products 128. DCN Diagnostics 129. Denka 130. Denka Seiken 131. Diagnostic Automation / Cortez Diagnostics 132. Diagnostics for the Real World (DRW) 133. DIALAB 134. DiaSorin 135. DiscoveryDX 136. DNA Electronics 137. Dolomite Microfluidics 138. Dynamiker Biotechnology (Tianjin) 139. E25Bio 140. Ebram Produtos Laboratoriais 141. ECO Diagnóstica 142. efyian 143. Eiken Chemical 144. Elabscience 145. Elena Diagnostic 146. ELG Medical 147. Ellume 148. EMPE Diagnostics 149. Era Biology 150. Eurobio Scientific 151. Evotech-Mirai Genomics (EMG) 152. Exhalation Medical Technology 153. EY Laboratories 154. FastSense Diagnostics 155. Fio 156. First Diagnostic 157. Firstep Bioresearch 158. Fluxergy 159. Focus Diagnostics 160. Foundation for Innovative New Diagnostics (FIND) 161. Frontage Laboratories 162. Frontida BioPharm 163. Fujirebio 164. Future HorizonS Scientific 165. Fyodor Biotechnologies 166. GaDia 167. GenBody 168. genedrive 169. GenePOC 170. Genesis Diagnostics 171. GenMark Diagnostics 172. GenPrime 173. GENSPEED Biotech 174. GeTein BioMedical 175. Ginolis 176. Glenbio 177. GoDx 178. Guangzhou Wondfo Biotech 179. Hangzhou AllTest Biotech 180. Hangzhou Biotest Biotech 181. Hangzhou Bosure Biotech 182. Hangzhou Genesis Biodetection & Biocontrol 183. Hangzhou Laihe Biotech 184. Hangzhou Testsea Biotechnology 185. Harvard University 186. HBI 187. Healgen Scientific 188. Hebei Times Medical Technology 189. Helix2 190. Hema Diagnostic Systems 191. Hemex Health 192. Henry Schein 193. HiberGene Diagnostics 194. HIGHTOP Biotech 195. Human Gesellschaft für Biochemica und Diagnostica 196. Humasis 197. iAssay 198. Ibn Rushd Medical & Scientific Equipment 199. ICT Diagnostics 200. Immunoshop 201. Immunostics 202. InBios International 203. Indian Council of Medical Research 204. InSilixa 205. Instadiagnostics 206. Instant NanoBiosensors 207. Institut Pasteur de Dakar 208. Intec Products 209. Integrated DNA Technologies 210. Interlab INTERAUTOMATIKA 211. Invenio Medical 212. J&G Biotech 213. J. Mitra 214. JAJ International 215. Jiangsu Dablood Pharmaceutical 216. JOYSBIO (Tianjin) Biotechnology 217. KAINOS Laboratories 218. Kephera Diagnostics 219. Kin Diagnostics 220. Köroglu Medical Devices 221. Lab Care Diagnostics 222. Lab21 223. Labmaster 224. Labsystems Diagnostics 225. LamdaGen 226. Leaflife Technology 227. LifeSign 228. Liming Bio-Products 229. LT LABS 230. Luminex 231. Luminostics 232. LumiraDx 233. Lumos Diagnostics 234. Maccura Biotechnology 235. Mass General Brigham 236. Massachusetts General Hospital 237. Massachusetts Institute of Technology 238. Maternova 239. MBio Diagnostics 240. MBiolog Diagnósticos 241. McKesson Medical-Surgical 242. Medcaptain Medical Technology 243. Medical Communications Associates 244. Medical Innovation Ventures 245. MedicalSystem Biotechnology 246. Mediclone Biotech 247. Medimprint 248. MEDISENSOR 249. MedMira 250. Medusa19 251. Menarini Silicon Biosystems 252. Menssana Research 253. Meridian Bioscience 254. Meril Life Sciences 255. Mesa Biotech 256. MH Medical 257. MicrosensDx 258. Mobidiag 259. Mobile Assay 260. Mokobio Biotechnology 261. Molbio Diagnostics 262. Mologic 263. MONDIALAB 264. Moroccan Foundation for Advanced Science Innovation & Research (MAScIR) 265. Mossman Associates 266. MP Biomedicals 267. Mylan 268. nal von minden 269. Nanobiosym 270. Nano-Ditech 271. NanoDx 272. NanoEnTek 273. Nanomix 274. National Institute of Infectious Diseases 275. Nectar Lifesciences 276. NextGen Invitro Diagnostics (NGIVD) 277. Nexus Dx 278. NG Biotech 279. Noul 280. NowAware 281. NOWDiagnostics 282. NTBIO Diagnostics 283. Nulife Care 284. Oasis Diagnostics 285. OMC Healthcare 286. Omega Diagnostics 287. One Milo 288. Ontera 289. OpGen 290. OPKO Health 291. Orangelife Comercio e Industria 292. Oranoxis 293. OraSure Technologies 294. Orchid Biomedical Systems 295. Oscar Medicare 296. Owen Mumford 297. Owlstone Medical 298. Pacific Image Electronics 299. PAI Life Sciences 300. PATH 301. PhageTech 302. Pinakin Pharmaceuticals 303. PointCare Technologies 304. Prechek Bio 305. Precision Biosensor 306. Predictive Laboratories 307. Premier Medical 308. PRIMA Lab 309. Pro Med Diagnostics 310. Proactive Diagnostics 311. Prominex 312. ProteinLogic 313. QIAGEN 314. Qualpro Diagnostics 315. QuantaSpec 316. QuantuMDx 317. Quaphaco 318. Quartzy 319. Quibasa-Bioclin 320. Quidel 321. Quimica Valaner 322. Radiometer Medical India 323. Randox Testing Services 324. Rapid Biosensor Systems 325. Rapid Diagnostics Group 326. Rapid Diagnostics ML 327. RapiGEN 328. RayBiotech 329. R-Biopharm 330. REAGEN 331. Relay Medical 332. Response Biomedical 333. Reszon Diagnostics International 334. Rheonix 335. Righton 336. RINGBIO 337. Roche 338. ROI Scientific 339. RPS Diagnostics 340. Rutgers University 341. SA Scientific 342. Sagentia 343. Savyon Diagnostics 344. Scanogen 345. SD BIOSENSOR 346. SEASUN BIOMATERIALS 347. Sedia Biosciences 348. Sekisui Chemical 349. Sekisui Diagnostics 350. Seloi Healthcare 351. SensDx 352. Sense Biodetection 353. Sepsitron 354. Shanghai Chemtron Biotech 355. Shanghai Kehua Bio-Engineering 356. Shenzhen Bioeasy Biotechnology 357. Sherlock Biosciences 358. Sight Diagnostics 359. SkillCell 360. Skolkovo Institute of Science and Technology 361. Span Biotech 362. Spartan Bioscience 363. SpeeDx 364. Spindiag 365. SSI Diagnostica 366. Stony Brook Medicine 367. Sugentech 368. Sure Bio-Tech 369. SureScreen Diagnostics 370. Swift Molecular Diagnostics 371. Sysmex Partec 372. Talis Biomedical 373. Tangen Biosciences 374. Tata Trusts 375. TAUNS Laboratories 376. Technogenetics 377. Teco Diagnostics 378. The eNose Company 379. The Inovie Group 380. Theranostica 381. Thermal Gradient 382. Thermo Fisher Scientific 383. TM Testing 384. Topcare Biotech 385. Trinity Biotech 386. TrivTech Dx 387. Tulip Diagnostics 388. Turk Lab 389. UCP Biosciences 390. ulti med Products 391. Unilatex.com 392. Unimed International 393. UNITAID 394. United States Department of Health and Human Services (HHS) 395. University of Oxford 396. University of Tokyo 397. UrSure 398. Ustar Biotechnologies 399. Vazyme Biotech 400. VedaLab 401. Veredus Laboratories 402. Vidant Health 403. VIDIA 404. Viola Diagnostic Systems 405. Vision Biotechnology 406. VivaChek Laboratories 407. VOGO 408. W.H.P.M. 409. Wageningen University & Research 410. WAMA Diagnóstica 411. Webb Diagnostic Technologies 412. Wellgistics 413. WELLS BIO 414. Wezi Medical Center 415. World Hepatitis Alliance 416. Wuhan UNscience Biotechnology 417. XCR Diagnostics 418. Xiamen Biotime Biotechnology 419. Xiamen Boson Biotech 420. Xinhua Healthcare Industry 421. Yaathum Biotech 422. Zephyr Biomedicals 423. Zhuhai Livzon Diagnostics 424. ZymeTx